Overview

The marketing authorisation for Zulvac 1 Ovis has been withdrawn at the request of the marketing-authorisation holder.

български (BG) (387.71 KB - PDF)

View

español (ES) (324.29 KB - PDF)

View

čeština (CS) (367.61 KB - PDF)

View

dansk (DA) (311.6 KB - PDF)

View

Deutsch (DE) (339.3 KB - PDF)

View

ελληνικά (EL) (425.96 KB - PDF)

View

français (FR) (340.13 KB - PDF)

View

italiano (IT) (335.8 KB - PDF)

View

latviešu valoda (LV) (411.71 KB - PDF)

View

lietuvių kalba (LT) (350.56 KB - PDF)

View

magyar (HU) (383.87 KB - PDF)

View

Malti (MT) (373.83 KB - PDF)

View

Nederlands (NL) (320.6 KB - PDF)

View

polski (PL) (381.01 KB - PDF)

View

português (PT) (329.18 KB - PDF)

View

română (RO) (327.6 KB - PDF)

View

slovenčina (SK) (357.21 KB - PDF)

View

slovenščina (SL) (375.83 KB - PDF)

View

Suomi (FI) (335.83 KB - PDF)

View

svenska (SV) (303.24 KB - PDF)

View

Product information

български (BG) (747.04 KB - PDF)

View

español (ES) (415.86 KB - PDF)

View

čeština (CS) (625.49 KB - PDF)

View

dansk (DA) (420.56 KB - PDF)

View

Deutsch (DE) (442.48 KB - PDF)

View

eesti keel (ET) (426.62 KB - PDF)

View

ελληνικά (EL) (744.06 KB - PDF)

View

français (FR) (441.63 KB - PDF)

View

hrvatski (HR) (487.06 KB - PDF)

View

íslenska (IS) (431.83 KB - PDF)

View

italiano (IT) (439.98 KB - PDF)

View

latviešu valoda (LV) (612.09 KB - PDF)

View

lietuvių kalba (LT) (492.04 KB - PDF)

View

magyar (HU) (645.11 KB - PDF)

View

Malti (MT) (643.64 KB - PDF)

View

Nederlands (NL) (428.46 KB - PDF)

View

norsk (NO) (426.93 KB - PDF)

View

polski (PL) (637.5 KB - PDF)

View

português (PT) (424.02 KB - PDF)

View

română (RO) (523 KB - PDF)

View

slovenčina (SK) (629.98 KB - PDF)

View

slovenščina (SL) (619.27 KB - PDF)

View

Suomi (FI) (412.23 KB - PDF)

View

svenska (SV) (434.1 KB - PDF)

View

Latest procedure affecting product information: IB/00017

21/06/2019

български (BG) (853.9 KB - PDF)

View

español (ES) (837.98 KB - PDF)

View

čeština (CS) (862.38 KB - PDF)

View

dansk (DA) (806.02 KB - PDF)

View

Deutsch (DE) (827.27 KB - PDF)

View

eesti keel (ET) (805.45 KB - PDF)

View

ελληνικά (EL) (877.4 KB - PDF)

View

français (FR) (824.01 KB - PDF)

View

íslenska (IS) (806.86 KB - PDF)

View

italiano (IT) (801.5 KB - PDF)

View

latviešu valoda (LV) (843.42 KB - PDF)

View

lietuvių kalba (LT) (1.38 MB - PDF)

View

magyar (HU) (853.89 KB - PDF)

View

Malti (MT) (847.1 KB - PDF)

View

Nederlands (NL) (824.2 KB - PDF)

View

norsk (NO) (804.7 KB - PDF)

View

polski (PL) (862.36 KB - PDF)

View

português (PT) (837.86 KB - PDF)

View

română (RO) (1.38 MB - PDF)

View

slovenčina (SK) (839.69 KB - PDF)

View

slovenščina (SL) (858.77 KB - PDF)

View

Suomi (FI) (824.89 KB - PDF)

View

svenska (SV) (805.81 KB - PDF)

View

Product details

Name of medicine
Zulvac 1 Ovis
Active substance
inactivated bluetongue virus, serotype-1
International non-proprietary name (INN) or common name
inactivated bluetongue virus, serotype-1
Species
Sheep
Anatomical therapeutic chemical veterinary (ATCvet) code
QI04AA02

Pharmacotherapeutic group

Immunologicals

Therapeutic indication

Active immunisation of sheep from 1.5 months of age for the prevention of viraemia caused by bluetongue virus, serotypes-1.

Onset of immunity: 21 days after completion of the primary vaccination scheme.

Duration of immunity: 12 months.

Authorisation details

EMA product number
EMEA/V/C/002335

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment.

Marketing authorisation holder
Zoetis Belgium SA

Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Marketing authorisation issued
05/08/2011
Revision
6

Assessment history

This page was last updated on

Share this page